Research programme: ROR gamma modulators - Amgen/Teijin Pharma
Alternative Names: ROR-gamma modulators - Amgen/Teijin PharmaLatest Information Update: 04 Nov 2017
At a glance
- Originator Amgen; Teijin Pharma
- Class Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Autoimmune-disorders in Japan
- 04 Nov 2017 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 31 Jul 2013 Early research in Autoimmune disorders in USA and Japan (unspecified route)